Bristol Myers Squibb (CGT Mfg) vs RoslinCT: CDMO Comparison
How does Bristol Myers Squibb (CGT Mfg) compare to RoslinCT for CAR-T manufacturing?
Side-by-side comparison of Bristol Myers Squibb (CGT Mfg) and RoslinCT on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Bristol Myers Squibb (CGT Mfg) has more FDA inspections on record (6 vs 1) — a deeper regulatory paper trail.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Bristol Myers Squibb (CGT Mfg) holds 1 active EMA GMP certificates; RoslinCT does not appear in EudraGMDP.
- Bristol Myers Squibb (CGT Mfg) appears as a manufacturing partner on more matched clinical programs (585 vs 0) — a broader sponsor book.
- Composite Signal Score: Bristol Myers Squibb (CGT Mfg) 91/100 vs RoslinCT 80/100 — a 11-point gap reflecting the combined quality, capacity and financial signal.
On a 13-modality CDMO landscape, both Bristol Myers Squibb (CGT Mfg) and RoslinCT qualify as CAR-T manufacturers; Bristol Myers Squibb (CGT Mfg) carries the higher composite Signal Score for CAR-T programs in this comparison.
What to evaluate for CAR-T programs
Both Bristol Myers Squibb (CGT Mfg) and RoslinCT qualify as CAR-T CDMOs. When choosing between them for CAR-T programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Vector supply
CAR-T needs a lentiviral or retroviral vector. Confirm whether the CDMO produces vector in-house or coordinates a supplier, and how that affects timelines and cost.
Autologous logistics & turnaround
Autologous CAR-T lives or dies on vein-to-vein time and chain-of-identity. Evaluate scheduling, apheresis handling, and cryo-logistics.
Closed, scalable processing
Closed and automated platforms reduce contamination risk and support parallel patient slots. Ask about cleanroom grade and concurrent-batch capacity.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.
Frequently asked: Bristol Myers Squibb (CGT Mfg) vs RoslinCT
How does Bristol Myers Squibb (CGT Mfg) compare to RoslinCT for CAR-T manufacturing?
On CDMO Signal's composite Signal Score, Bristol Myers Squibb (CGT Mfg) is 91/100 and RoslinCT is 80/100; Bristol Myers Squibb (CGT Mfg) has 6 FDA inspections on record vs 1 for RoslinCT; European coverage is 2 active EMA+MHRA certificates for Bristol Myers Squibb (CGT Mfg) vs 1 for RoslinCT. Both are tracked in the CDMO Signal directory as CAR-T CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, Bristol Myers Squibb (CGT Mfg) or RoslinCT?
Both Bristol Myers Squibb (CGT Mfg) and RoslinCT maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Bristol Myers Squibb (CGT Mfg) has 6 FDA inspections on record; RoslinCT has 1.
How do Bristol Myers Squibb (CGT Mfg) and RoslinCT compare on European GMP coverage?
Bristol Myers Squibb (CGT Mfg) holds 1 active EMA GMP certificate and 1 MHRA / UK certificate. RoslinCT holds 0 active EMA GMP certificates and 1 MHRA / UK certificate. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — Bristol Myers Squibb (CGT Mfg) or RoslinCT?
Bristol Myers Squibb (CGT Mfg) is matched to 585 ClinicalTrials.gov records as a manufacturing partner; RoslinCT is matched to 0. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
Which is better for CAR-T manufacturing — Bristol Myers Squibb (CGT Mfg) or RoslinCT?
Both Bristol Myers Squibb (CGT Mfg) and RoslinCT are tagged as CAR-T CDMOs in our directory, so both are credible options for CAR-T programs. The most important differentiator for CAR-T selection is typically vector supply: CAR-T needs a lentiviral or retroviral vector. Confirm whether the CDMO produces vector in-house or coordinates a supplier, and how that affects timelines and cost. Review each CDMO's profile and inspection record before shortlisting.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →